Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: A meta-analysis

Table 8 Measurements of faecal pyruvate kinase isoenzyme type M2 in stool samples of healthy individuals

Reference	No. of healthy participants	Test-negative participants (%)	Colonoscopy (yes/no)	Specificity (%)
Belluti et al[52], 2005	2787	91.6	No	97.4 (e)
McLoughlin et al[51], 2005	97	98	Yes	98
Tonus et al[41], 2006	42	93	Yes	93
Ewald et al[37], 2007	1906	90.4	No
Haug et al[33], 2007	917	78.6	No
Koss et al[8], 2008	13	100.0	Yes	100.0
Tonus et al[49], 2009	4854	91.2	No	93.4 (e)
Möslein et al[10], 2010	796	89.5	Yes	89.5
Sum	11 412
mean ± SD		91.5 ± 6.4		95.2 ± 3.9

e: Estimated specificities calculated by authors based on the sensitivity of faecal pyruvate kinase isoenzyme type M2 for colorectal cancer (CRC) and advanced neoplasia, and the prevalence of CRC and advanced adenoma.